<html><head><title>2024-02-16</title><link rel="stylesheet" type="text/css" href="static/table.css"/></head><body><table id="container">
  <thead>
    <tr style="text-align: right;">
      <th role="columnheader">No.</th>
      <th role="columnheader">capSize</th>
      <th role="columnheader">stock</th>
      <th role="columnheader">chance</th>
      <th role="columnheader">risk</th>
      <th role="columnheader">tags</th>
      <th role="columnheader">Volatility</th>
      <th role="columnheader">YTD%</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>1</td>
      <td>Mega</td>
      <td><a href="https://xueqiu.com/S/TSM">TSM<br>Taiwan Semiconductor Manufacturing Company</a></td>
      <td>1. Investors are bullish on the chance for more gains in shares of Nvidia Corp.’s top memory supplier SK Hynix Inc.<br>2. Taiwan Semiconductor Manufacturing Co. gained about $42 billion of market value after investors bet the chipmaker to Nvidia Corp. and Apple Inc. will become one of the biggest winners of an AI development frenzy.<br>3. Taiwan Semiconductor Manufacturing is a crucial supplier to companies like Nvidia and AMD.<br>4. The move to build an artificial general intelligence – an AI that could surpass human intelligence in a range of fields – presents a significant opportunity for Taiwan Semiconductor Manufacturing.</td>
      <td>1. The stock market has benefited from strong investor interest in chip stocks, but there may be risks associated with a potential market correction.<br>2. The company's success is closely tied to the demand for artificial intelligence technology, which may face regulatory and ethical challenges.</td>
      <td>semiconductor industry<br>artificial intelligence<br>chip stocks<br>metaverse<br>investment opportunity</td>
      <td>366.12</td>
      <td>33.97</td>
    </tr>
    <tr>
      <td>2</td>
      <td>Small</td>
      <td><a href="https://xueqiu.com/S/MPW">MPW<br>Medical Properties Trust</a></td>
      <td>1. The company will host a conference call and webcast to discuss its fourth quarter and year-end 2023 financial results, indicating transparency and potential for positive updates<br>2. Investor appetite for risky stocks has come back in recent months, suggesting potential for increased interest in healthcare REITs like Medical Properties Trust<br>3. The January inflation numbers negatively affected REIT stocks, including Medical Properties Trust, but the market may experience an upswing in the future</td>
      <td>1. The upheavals of 2023 rattled the housing market and created uncertainty for real estate investment trusts (REITs), suggesting potential challenges for Medical Properties Trust<br>2. Steward Health Care System, the largest tenant of Medical Properties Trust, has engaged restructuring advisers due to financial problems, posing a risk to the company's revenue</td>
      <td>Healthcare REIT<br>Financial transparency<br>Market uncertainty<br>Tenant risk<br>Inflation impact</td>
      <td>567.71</td>
      <td>-22.33</td>
    </tr>
    <tr>
      <td>3</td>
      <td>Middle</td>
      <td><a href="https://xueqiu.com/S/ET">ET<br>nan</a></td>
      <td>1. Energy Transfer LP reported higher adjusted earnings for the fourth quarter of 2023 and expects earnings to grow in 2024.<br>2. The company expects its 2024 adjusted EBITDA to range between $14.5 billion and $14.8 billion, indicating a 7% increase from 2023.<br>3. Energy Transfer's growth capital expenditures for 2024 will range from $2.4 billion to $2.6 billion.</td>
      <td>1. Investors need to consider the potential impact of any regulatory changes or shifts in the energy market on Energy Transfer's business operations and financial performance.<br>2. Fluctuations in energy prices and demand could affect the company's future earnings and cash flow.</td>
      <td>Energy<br>Transportation<br>Earnings<br>Financial Outlook<br>Investment</td>
      <td>480.91</td>
      <td>7.21</td>
    </tr>
    <tr>
      <td>4</td>
      <td>Large</td>
      <td><a href="https://xueqiu.com/S/UBER">UBER<br>Uber</a></td>
      <td>1. Longtime money-losing ride-share companies Uber Technologies and Lyft have surprised naysayers by racing toward steady profits.<br>2. 2023 marked Uber’s first year of being profitable as a public company.<br>3. Uber outlined better long-term financial goals during its investor day.<br>4. The buyback announcement highlights UBER's shareholder-friendly attitude.</td>
      <td>1. Despite the recent profitability, there is still a risk associated with the ride-share industry.<br>2. Competition from other ride-share companies could impact Uber's market share and profitability.<br>3. The company's ability to maintain profitability in the future is uncertain.</td>
      <td>Uber Technologies<br>ride-share industry<br>profitability<br>competition<br>financial goals</td>
      <td>1020.52</td>
      <td>40.40</td>
    </tr>
    <tr>
      <td>5</td>
      <td>Small</td>
      <td><a href="https://xueqiu.com/S/M">M<br>Macy's</a></td>
      <td>1. Macy's has announced the launch of State of Day, a new restwear, sleepwear and innerwear brand, which adds to the company's momentum in reimagining its private brands portfolio.<br>2. The company's consistent battle with inflation may lead to bargain hunting and increased sales for discount retailer stocks, which could benefit Macy's in the long run.</td>
      <td>1. Macy's foot traffic in the US dropped 2.49% in 2023, indicating a potential challenge in attracting customers to physical stores.<br>2. The company is facing challenges such as a take-private offer, changes to the department store's fleet, and potential takeover bids, which may impact its future direction.</td>
      <td>Retail<br>Private Brands<br>Inflation<br>Foot Traffic<br>Takeover Bids</td>
      <td>583.47</td>
      <td>20.32</td>
    </tr>
    <tr>
      <td>6</td>
      <td>Small</td>
      <td><a href="https://xueqiu.com/S/CRSP">CRSP<br>nan</a></td>
      <td>1. CRISPR Therapeutics has shown improving price performance, earning an upgrade to its IBD Relative Strength Rating.<br>2. The company is focused on creating transformative gene-based medicines for serious diseases, and has announced conditional marketing authorization for its gene edited therapy, CASGEVY.</td>
      <td>1. The company doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.<br>2. Investors' focus is likely to be on the company's progress with the launch activities of the newly approved gene therapy, Casgevy (exa-cel).</td>
      <td>Biopharmaceutical<br>Gene Editing<br>Therapeutic Programs<br>Earnings Report<br>Conditional Marketing Authorization</td>
      <td>523.04</td>
      <td>19.66</td>
    </tr>
    <tr>
      <td>7</td>
      <td>Middle</td>
      <td><a href="https://xueqiu.com/S/DASH">DASH<br>DoorDash</a></td>
      <td>1. DoorDash reported fourth-quarter revenue of $2.30 billion, topping estimates<br>2. Adjusted EBITDA of $363 million was better than expected<br>3. Positive forward guidance from Lyft and Uber may indicate growth potential for food delivery services</td>
      <td>1. DoorDash forecast a quarterly profitability metric below Wall Street expectations<br>2. Higher labor costs may impact profitability<br>3. Gig economy worker strikes could disrupt operations and lead to increased costs</td>
      <td>Food Delivery<br>Gig Economy<br>Earnings Report<br>Marketplace Growth<br>Labor Costs</td>
      <td>620.92</td>
      <td>31.20</td>
    </tr>
    <tr>
      <td>8</td>
      <td>Small</td>
      <td><a href="https://xueqiu.com/S/ALKS">ALKS<br>Alkermes</a></td>
      <td>1. Alkermes stock saw its Relative Strength Rating improve from 69 to 75, indicating a potential rebound in the stock's performance.<br>2. The company's earnings and revenues outpaced estimates in the fourth quarter of 2023, driven by strong growth in proprietary products.<br>3. Robust revenue growth and strategic focus are likely to propel Alkermes into 2024, indicating positive prospects for the company.<br>4. Alkermes possesses the right combination of key ingredients for a likely earnings beat in its upcoming report, indicating potential positive momentum for the stock.</td>
      <td>1. It might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers to assess potential risks associated with the stock's performance.<br>2. Involvement in the healthcare space can subject the company to regulatory and market uncertainties, which may pose risks to its financial performance.<br>3. Market volatility and uncertainties in the biotech industry may pose risks to Alkermes' stock performance.<br>4. Investors should carefully monitor the company's financial expectations for 2024 and consider potential risks associated with those projections.</td>
      <td>biopharmaceutical<br>earnings<br>revenue growth<br>healthcare<br>stock performance</td>
      <td>1201.28</td>
      <td>21.13</td>
    </tr>
    <tr>
      <td>9</td>
      <td>Mega</td>
      <td><a href="https://xueqiu.com/S/KO">KO<br>nan</a></td>
      <td>1. Coca-Cola has increased its quarterly dividend by approximately 5.4% to 48.5 cents per share, yielding 3.3%.<br>2. The company reported upbeat earnings and surpassed analyst expectations in sales, reflecting a resilient US consumer.</td>
      <td>1. Coca-Cola and PepsiCo are reporting year-over-year volume declines in North American markets, offset by price hikes alongside inflated food prices.<br>2. Kraft Heinz net sales fell short of expectations and experienced a rare decline as consumers cut back.</td>
      <td>Beverage industry<br>Consumer habits<br>Earnings report<br>Dividend increase<br>Resilient US consumer</td>
      <td>339.37</td>
      <td>1.26</td>
    </tr>
  </tbody>
</table><script src="static/tablesort.min.js"></script><script src="static/tablesort.number.min.js"></script><script>new Tablesort(document.getElementById("container"));</script></body></html>